Zoetis to expand animal vaccine research and manufacturing in China

Operations to focus on development and manufacturing of vaccines for pigs, cattle, fish and companion animals tailored to the animal health needs of China.

April 26, 2018

5 Min Read
Zoetis to expand animal vaccine research and manufacturing in China

Source: Zoetis

Zoetis begins construction of state-of-the-art vaccine manufacturing and research and development facilities in Suzhou. The new facility will focus on development and production of quality vaccines for swine, cattle, fish and companion animals that help protect against the strains of diseases prevalent in China. Zoetis also marked the opening of an interim research and development facility nearby in Suzhou where the company’s PHARMAQ business will begin to develop vaccines for the farmed fish industry in China; the first such research and development center established by a multinational company to concentrate on aquaculture in mainland China. The events affirmed the company’s continued investment in and commitment to innovation, manufacturing excellence, and growth in China.

“We at Zoetis have a deep understanding of the animal health challenges that livestock farmers and veterinary professionals in China face every day,” says Mike Wang, senior vice president, Greater China Cluster for Zoetis. “With this new center for vaccine innovation co-located with expanded manufacturing capabilities in Suzhou and a team of highly trained field representatives, we are well-positioned to help China’s livestock farmers answer increasing demand for a safe and abundant supply of pork, milk, beef and fish. And we can support veterinarians as they strive to help pets live longer, healthier lives.”

Zoetis is a leading multi-national animal health company in China with revenue of $174 million (USD) in China in 2017. Zoetis began operations in China in 1995 and has approximately 600 employees and commercial headquarters in Shanghai. The product portfolio includes more than 80 product lines that span five product categories, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products, which serve six core animal species — pigs, dairy cattle, poultry, fish, dogs and cats. China is the fifth largest market for Zoetis by annual revenue worldwide.

Expanding innovation in China
The planned vaccine research and development (research and development) center in Suzhou will expand and strengthen the innovation under way at the Zoetis research and development laboratory in Beijing, which opened in 2015.

“The future work of our scientists in Suzhou will help accelerate the development of quality vaccines tailored to meet the animal health needs of the China market, and it will enable expansion from our initial focus on vaccines for swine to those for cattle and fish as well as for companion animals,” says Catherine Knupp, executive vice president and president of Research and Development at Zoetis. “Zoetis scientists from our laboratory in Beijing and our global R&D network will collaborate with the Suzhou-based R&D team, helping speed the introduction of Zoetis technologies and processes into the development of high-quality vaccines and medicines for China.” The animal vaccines market in China was valued at more than $1.8 billion in 2017.

At the start-up research and development laboratory in Suzhou, PHARMAQ scientists will primarily concentrate on acquiring in-depth knowledge of the disease threats within the Chinese aquaculture sector. This know-how will serve as the foundation to develop safe and effective vaccines for the aquaculture industry in China. Vaccines are expected to become an important health management tool for China’s aquaculture industry to help control the diseases that pose the greatest threat to this industry. China is the world`s largest aquaculture nation, producing approximately 50 million metric tonnes of farmed fish in 2016, which represent 63% of global production. Increased reliance on vaccines to control disease could help reduce the use of antibiotics to treat bacterial disease in farmed fish. Once Zoetis completes construction on the new combined research and development and manufacturing facility, research and development operations will transition to the new facility.

Increasing manufacturing capacity and capabilities in China
The new innovation and manufacturing facility in Suzhou will include 43,000 square meters of vaccine manufacturing operations and laboratory space. Zoetis expects to complete construction and Good Manufacturing Practices certification by the Chinese Ministry of Agriculture by 2021.

“We at Zoetis view China as a global center for high-quality manufacturing as well as innovation,” says Roman Trawicki, executive vice president and president of Global Manufacturing and Supply at Zoetis, who officiated at the groundbreaking ceremony. “The completion of this new vaccine manufacturing facility in Suzhou will establish a center of excellence for the production of quality vaccines tailored specifically to the needs of the Chinese market. It will broaden our manufacturing capacity and capabilities in China.”

The site will feature state-of-the-art technologies for the manufacture of viral and bacterial vaccines and will include pilot scale manufacturing for the development of new vaccine products. Zoetis expects to add approximately 100 new research and development and manufacturing positions at the facility during the next two years.

The new facility will become the company’s second vaccine manufacturing site in China. In 2017, Zoetis became the sole owner of its former joint venture vaccine manufacturing site in Jilin where the company has produced vaccines for swine tailored to the needs of the Chinese market since 2011. Innovative products developed there include Rui Lan An, a specialized vaccine launched in 2013 to help control highly pathogenic porcine reproductive and respiratory syndrome identified in China. In 2016, Zoetis also launched Rui Lan Wen, the first combination vaccine approved in China to help protect pigs against classical swine fever and porcine reproductive and respiratory syndrome prevalent there.

The new facility will also become the company’s second global manufacturing and supply facility in Suzhou. Zoetis opened a state-of-the-art facility there in 2015 where it produces medicated feed additive products as well as water soluble and pre-mix products used to help raise healthy pigs, cattle and poultry. 

Subscribe to Our Newsletters
National Hog Farmer is the source for hog production, management and market news

You May Also Like